Ep. 255, Chapter 4: Executable Exits with Yaniv Sneor

36:34 – 44:39

Sneor points out that that, while Mid Atlantic Bio Angels supports and guides their portfolio companies through liaisons, they do not drive exits; the biotech management teams are expected to possess or acquire that capability. Additionally, Sneor states that opportunities in "buzzy" therapeutic areas like GLP-1s face no less scrutiny. Future market landscape, the biotech’s timeline for acquisition, a robust patent estate and a unique value proposition all must be considered. MAB Angels rarely fills a round alone, but they only refer deals to syndicate partners once they have made an investment decision themselves, which serves as a strong endorsement.